| Nach 1 Jahr | ohne Bestrahlung | Mamillenbestrahlung | |
| Gynäkomastie | 71% | 28% | P <0.001 |
| Brustvergrößerung | 78% | 44% | P <0.001 |
| Brustempfindlichkeit | 75% | 43% | P <0.001, |
| Nach 1 Jahr | Schein - Bestrahlung | Mamillenbestrahlung | |
| Gynäkomastie | 85% | 52% | P <0.001 |
| Gynäkomastie ≥ 5cm | 50% | 11,5% | |
| moderate bis schwere Gynäkomastie | 91% | 83% | |
| Brustschmerz |
| Gruppe | keine Bestrahlung | Mamillenbestrahlung | Tamoxifen 10mg/24 Wochen | |
| Nach 1 Jahr | 51 Pat. | 50 Pat. | 50 Pat. | |
| Gynäkomastie | 35 | 17 | 4 | p < 0,008 |
| Brustschmerz | 29 | 3 | 15 | p < 0,02 |
| Gruppe | keine Bestrahlung | Mamillenbestrahlung | |
| Nach 1 Jahr | 53 Pat. | 72 Pat. | |
| Gynäkomastie | 50,8 % | 15,8% | p < 0,001 |
| Brustschmerz | 49,2% | 36,4% | n.s. |
| Leiden unter Gynäkomastie | 29,5% | 11,4% |
Leitlinie Gynäkomastie
J Urol Urogynäkol 15(2008): 12 - 14
2.) Widmark A, et al.:
Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3.
Urology. 61(2003):145-51
Universität Umeå
3.) Tyrrell CJ, et al.:
Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.
IJROBP 60(2004):476-83
Plymouth, UK
4.) Perdonà S, et al.:
Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial.
Lancet Oncol. 6(2005):295-300.
Neapel
5.) Ozen H, et al.:
Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and/or breast pain?
J Urol. 184(2010):519-24
Ankara
6.) Alfthan O, Kettunen K.:
The effect of roentgen ray treatment of gynecomastia in patients with prostatic carcinoma treated with estrogenic hormones: a preliminary communication.
J Urol 94(1965):604–6.
7.) Chou JL, Easley JD, Feldmeier JJ et al.:
Effective radiotherapy in palliating mammalgia associated with gynecomastia after DES therapy.
IJROBP 15(1988):749–51.
8.) Fass DJ, Steinfeld A, Brown J et al.:
Radiotherapeutic prophylaxis of estrogeninduced gynecomastia: a study of late sequela.
IJROBP 12(1986):407–8.
9.) Di Lorenzo G, Perdona S, de Placido S et al.:
Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
J Urol 174(2005):2197–203.
10.) Metzger H, Junker A, Voss AC.:
Die Bestrahlung der Brustdrüsen als Prophylaxe der östrogeninduzierten Gynäkomastie beim Prostatakarzinom.
Strahlenther 156(1980):102–4.
11.) van Poppel H, Tyrrell CJ, Haustermans K et al.:
Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.
Eur Urol 47(2005):587–92.
12.) Rupp N, Grünberg G.:
Mamma-Bestrahlung vor Hormongabe bei Patienten mit Prostatakarzinom.
Strahlentherapie 148(1974):35–8.
13.) See WA, Wirth M, McLeod DG et al.:
Bicalutamide as immediate therapy, either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: First analysis of the Early Prostate Cancer Program.
J Urol 168(2002):429–35.
14.) Wolf H, Madsen PO, Vermund H.:
Prevention of estrogen-induced gynecomastia by external irradiation.
J Urol 102(1969):607–9
